New Hepatocyte Genetic Variation Panel for Better Early Toxicity Testing and Improved Clinical Success
February 7, 2011 - With 90% of new drugs failing during clinical trials, the need to bring compounds to market efficiently remains a challenge. Unanticipated drug-induced toxicity represents a major obstacle. Every patient can present a different response to drug treatments (male versus female, environmental effects, etc.). Charles River now offers Varigenix™, a hepatocyte-based genetic variation panel representing genetic variability comparable to the human population and a convenient, effective and early solution to the problem of predicting Type B adverse drug reactions.
Varigenix™ is a 24-strain hepatocyte panel that makes it possible to predict potential drug toxicity in human subpopulations prior to the start of clinical trials. Four panels for genetic variation analysis are available, with each consisting of cryopreserved BXD mouse hepatocytes. The BXD strains have been extensively genotyped and phenotyped, with the parent strain (C57BL/6J and DBA/2J) of each panel fully sequenced. Any genetic difference between these two strains can lead to important differences among the BXD family of strains in the way that they respond to drugs.
The standard panel configuration includes:
With 80+ strains available, your customized panel can reflect as broad a genetic variation as needed to assess first-run toxicity screening or more in-depth investigation.
For more effective lead optimization and candidate screening earlier in your drug development plan, you can rely on the Varigenix™ hepatocyte screening panel to assist your evaluation of genetic variation in drug toxicity testing, environmental toxin exposure, drug development and other investigative uses. Please contact us at askcharlesriver@crl.com for further details.